Holen Sie sich die Stockscreener-App
10.80
0.52%
-0.06
Schlusskurs vom Vortag:
$10.86
Offen:
$10.88
24-Stunden-Volumen:
57,967
Relative Volume:
0.03
Marktkapitalisierung:
$960.33M
Einnahmen:
$71.64M
Nettoeinkommen (Verlust:
$-294.57M
KGV:
-3.2258
EPS:
-3.348
Netto-Cashflow:
$-84.46M
1W Leistung:
-7.89%
1M Leistung:
-20.50%
6M Leistung:
+26.36%
1J Leistung:
+29.23%
1-Tages-Spanne:
$10.75
$10.95
1-Wochen-Bereich:
$10.66
$12.00
52-Wochen-Spanne:
$7.3575
$13.90
Kura Oncology Inc Stock (KURA) Company Profile
Firmenname
Kura Oncology Inc
Sektor
Branche
Telefon
(858) 500-8800
Adresse
4930 DIRECTORS PLACE, SUITE 500, SAN DIEGO, CA
Compare KURA vs VRTX, REGN, MRNA, ARGX, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
KURA
Kura Oncology Inc
|
10.79 | 966.11M | 71.64M | -294.57M | -84.46M | -3.348 |
VRTX
Vertex Pharmaceuticals Inc
|
521.60 | 132.40B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
789.31 | 81.95B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
193.83 | 77.78B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
957.69 | 60.20B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.53 | 42.84B | 742.00K | -1.37B | -1.07B | -7.0731 |
Kura Oncology Inc Stock (KURA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-14 | Eingeleitet | Lake Street | Buy |
| 2025-09-04 | Eingeleitet | Guggenheim | Neutral |
| 2025-02-06 | Herabstufung | BTIG Research | Buy → Neutral |
| 2024-10-24 | Eingeleitet | UBS | Buy |
| 2024-10-14 | Herabstufung | Stifel | Buy → Hold |
| 2023-12-22 | Eingeleitet | Mizuho | Buy |
| 2023-08-11 | Eingeleitet | BofA Securities | Buy |
| 2023-07-27 | Eingeleitet | Scotiabank | Sector Perform |
| 2023-05-17 | Eingeleitet | BTIG Research | Buy |
| 2023-01-31 | Eingeleitet | Stifel | Buy |
| 2022-07-12 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-02-15 | Eingeleitet | Jefferies | Buy |
| 2021-05-05 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2020-12-07 | Bestätigt | H.C. Wainwright | Buy |
| 2020-12-03 | Eingeleitet | Stifel | Buy |
| 2020-11-05 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2020-07-07 | Eingeleitet | Credit Suisse | Outperform |
| 2020-05-05 | Eingeleitet | Barclays | Overweight |
| 2019-07-18 | Eingeleitet | Deutsche Bank | Buy |
| 2018-11-09 | Eingeleitet | Piper Jaffray | Overweight |
| 2018-08-01 | Eingeleitet | H.C. Wainwright | Buy |
| 2016-10-13 | Fortgesetzt | Leerink Partners | Outperform |
| 2016-01-22 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2015-12-30 | Eingeleitet | Oppenheimer | Outperform |
| 2015-12-16 | Eingeleitet | Citigroup | Buy |
Alle ansehen
Kura Oncology Inc Aktie (KURA) Neueste Nachrichten
Form 144 KURA ONCOLOGY For: 25 September By Investing.com - Investing.com India
Shares from a stock option exercise are proposed for sale by a Kura Oncology (KURA) officer, valued at $224,514. - Stock Titan
Why (KURA) Price Action Is Critical for Tactical Trading - news.stocktradersdaily.com
Kura Oncology stock holds at USD 11.73 as Caspian launches - AD HOC NEWS
Kura Oncology, Inc. (KURA) Stock Analysis: A Biotech Innovator with a 173% Potential Upside - DirectorsTalk Interviews
KURA News | KURA ONCOLOGY INC (NASDAQ:KURA) - ChartMill
Kura Oncology to present at three investor conferences in September - scanx.trade
Kura Oncology Q2 2026 Earnings Call Transcript - Benzinga
Kura Oncology at Morgan Stanley conference: early sales, bigger bets By Investing.com - Investing.com Nigeria
Kura Oncology at Morgan Stanley conference: early sales, bigger bets - Investing.com
Kura Oncology (KURA) awards CFO 450,000 stock options - Stock Titan
Kura Oncology (KURA) CFO files initial ownership report with no trades - Stock Titan
Kura Oncology Maintains 49.2% Stake in Caspian Therapeutics Following $50M Series A Funding - Kalkine Media
symbol__ Stock Quote Price and Forecast - CNN
Kura Spins Out Caspian With $50m To Test Menin Inhibition In Diabetes - insights.citeline.com
Kura assets flow to Caspian for cardiometabolic indications - BioWorld News
Kura Oncology Pivots Diabetes Strategy Into $50 Million Subsidiary - AOL.com
Kura Oncology Raises $50M for Cardiometabolic Subsidiary Caspian - minichart.com.sg
KURA Oncology Launches Caspian Therapeutics, Shifting Focus Whil - GuruFocus
Kura Oncology at cantor conference: rapid launch, wider ambitions - Investing.com India
Kura Oncology at cantor conference: rapid launch, wider ambitions By Investing.com - Investing.com Canada
Kura Oncology, Inc. Enters into Contribution and License and Intercompany Services Agreement with Caspian Therapeutics, Inc - marketscreener.com
Kura Oncology Launches Caspian Therapeutics With $50 Million Funding - marketscreener.com
Kura Oncology Appoints Jennifer Fulk as New CFO - The Globe and Mail
Kura Oncology Establishes Caspian Partnership for Cardiometabolic Focus - TipRanks
Kura Oncology Launches Caspian Therapeutics with $50 Million Financing to Advance Menin Inhibition as a Potential Disease-Modifying Approach for Diabetes - The Manila Times
Eli Lilly is among investors in a new diabetes company with $50 million - Stock Titan
KURA: Strong commercial momentum and advancing late-stage pipeline position for major growth - TradingView
KURA: Strong commercial momentum and advancing late-stage pipeline position for major growth by 2028 - TradingView
Kura Oncology at Wells Fargo conference: launch gains and pipeline breadth - investing.com
Kura Oncology Names Jennifer Fulk as Chief Financial Officer Effective September 8, 2026 - Kalkine Media
Kura Oncology Names Jennifer Fulk Chief Financial Officer - Minichart
Kura Oncology, Inc. Announces Chief Financial Officer Changes, Effective September 8, 2026 - marketscreener.com
Kura Oncology Names Jennifer Fulk Finance Chief - marketscreener.com
Jennifer Fulk named CFO of Kura Oncology, replacing Troy E. Wilson and Thomas Doyle - TradingView
New Kura Oncology (KURA) CFO gets 450,000 options and up to 18 months of severance pay - Stock Titan
A former Eli Lilly executive takes Kura's top finance job - Stock Titan
Four new hires get options to buy 48,450 Kura shares - Stock Titan
Price-Driven Insight from (KURA) for Rule-Based Strategy - Stock Traders Daily
Kura Oncology (KURA) Stock Looks Fully Priced After Its 56% Run - finance.yahoo.com
KURA Stock Gains 37.6% in a Month: Here's What You Need to Know - TradingView
Kura Oncology to Participate in Three Investor Conferences in September - GlobeNewswire
Kura Oncology (KURA) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
Mizuho Securities Maintains Kura Oncology(KURA.US) With Buy Rating, Maintains Target Price $25 - Moomoo
Cancer Biotech Kura Oncology Rallies to New High After CEO’s Stock Purchase - Barron's
Kura Oncology (KURA) Moves 8.3% Higher: Will This Strength Last? - qz.com
Kura Oncology: 'Strong Buy': Ziftomenib AML Expansions With Different Regimens Could Boost KOMZIFTI's Prospects - Seeking Alpha
Kura Oncology Shares Rise After CEO Purchases 100,000 Shares - marketscreener.com
Kura Oncology stock jumps after CEO buys $1.24M in shares - Investing.com Nigeria
Kura Oncology CCO Brian Powl sells $51,663 in shares By Investing.com - Investing.com India
Kura Oncology CEO Troy Wilson buys $1.24 million Kura shares By Investing.com - Investing.com South Africa
Finanzdaten der Kura Oncology Inc-Aktie (KURA)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.76%
0.26%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):